Physician profile
David Hayes
NPI 1295725943
$6,527.65
in general payments reported to CMS, 2019-2025
50 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $586 · 2021: $1,610 · 2022: $1,265 · 2023: $990 · 2024: $522 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $862.06 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $777.25 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $724.64 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $466.96 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $345.94 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $320.00 | 2019-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $299.99 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $263.97 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.62 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $211.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $193.51 | 2022-2025 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $171.26 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $170.00 | 2019-2022 | |
| Astellas Pharma US INC | $131.50 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.73 | 2019-2023 | Trulance, Xifaxan |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$97.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.